CONSERVE PLUS TOTAL RESURFACING HIP SYSTEM

FDA Premarket Approval P030042

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for theconserve plus total resurfacing hip system. The conserve plus total resurfacing hip system is a single use device intended for hybrid fixation utilizing cemented femoral head component and cementless acetabular component. Theconserve plus total resurfacing hip system is intended for use in resurfacing hiparthroplasty for reduction or relief of pain and/or improved hip function in skeletally maturepatients having the following conditions:1) non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis,traumatic arthritis, avascular necrosis, or dysplasia/ developmental dislocation of thehip (ddh), or2) inflammatory arthritis such as rheumatoid arthritis. The conserve plus total resurfacing hip system is intended for patients who, due to theirrelatively younger age or increased activity level, may not be suitable for traditional total hiparthroplasty due to an increased possibility of requiring future ipsilateral hip joint revision.

DeviceCONSERVE PLUS TOTAL RESURFACING HIP SYSTEM
Generic NameProsthesis, Hip, Semi-constrained, Metal/metal, Resurfacing
ApplicantMicroPort Orthopedics Inc.
Date Received2003-09-30
Decision Date2009-11-03
Notice Date2009-11-18
PMAP030042
SupplementS
Product CodeNXT 
Docket Number09M-0540
Advisory CommitteeOrthopedic
Expedited ReviewYes
Combination Product No
Applicant Address MicroPort Orthopedics Inc. 5677 Airline Rd arlington, TN 38002
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P030042Original Filing
S004 2010-08-27 Real-time Process
S003 2010-01-21 Normal 180 Day Track No User Fee
S002 2010-01-21 Normal 180 Day Track No User Fee
S001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.